The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 22, 2022

Filed:

Aug. 24, 2017
Applicant:

Novo Nordisk A/s, Bagsvaerd, DK;

Inventors:

Brad Warren Van Orden, Seattle, WA (US);

Jakob Oest Wielandt, Farum, DK;

Thomas Dedenroth Miller, Seattle, WA (US);

Tinna Bjoerk Aradottir, Copenhagen, DK;

Pete Brockmeier, Copenhagen V, DK;

Henrik Bengtsson, Taastrup, DK;

Assignee:

Novo Nordisk A/S, Bagsvaerd, DK;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G16H 20/17 (2018.01); G16H 50/50 (2018.01); G16H 10/60 (2018.01); G16H 50/30 (2018.01); G16H 50/20 (2018.01); G16H 40/63 (2018.01); A61M 5/168 (2006.01); A61M 5/315 (2006.01); H04H 60/82 (2008.01); C12Q 1/54 (2006.01);
U.S. Cl.
CPC ...
G16H 20/17 (2018.01); A61M 5/31568 (2013.01); G16H 10/60 (2018.01); G16H 40/63 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01); A61M 2205/3584 (2013.01); A61M 2230/201 (2013.01);
Abstract

Systems and methods for treating a subject are provided. A first dataset comprising timestamped autonomous glucose measurements of the subject over a first time course is obtained. A second dataset, associated with a standing insulin regimen for the subject over the first time course and comprising insulin medicament records, is also obtained. Each record comprises a timestamped injection event including an amount and type of insulin medicament injected into the subject by an insulin pen. The first and second datasets serve to calculate a glycaemic risk measure and an insulin sensitivity factor of the subject during the first time course, which are used to obtain a basal titration schedule and a fasting blood glucose profile model over a subsequent second time course for the subject. The model predicts the fasting blood glucose level of the subject based upon amounts of basal insulin medicament injected into the subject.


Find Patent Forward Citations

Loading…